BioTuesdays

Category - Developments

Titan Pharmaceuticals Logo

Titan’s Probuphine featured in Fortune

The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance...

antibiotic

Canadian scientists discover new antibiotic

Canadian scientists say they have discovered the first new antibiotic in three decades, and that their research suggests it may potentially be effective at killing two worrisome superbugs: Pseudomonas aeruginosa and...

ZappRx

ZappRx in $25-million Series B financing

Closely-held ZappRx closed a $25-million Series B funding led by Qiming US Healthcare Fund, with participation from SR One, which led ZappRx’s Series A round in 2014, and GV, formerly Google Ventures. ZappRx is a...

Appili Therapeutics

Appili to receive funding for new antibiotic

Closely-held Appili Therapeutics will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support development of ATI-1503, an antibiotic...

BioTime

BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology. The formation of AgeX continues the implementation of...

Jaguar Animal Health

Jaguar, Napo update commercial activities

Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals, which are in the process of merging, updated their commercial activities. Jaguar is launching a national TV advertising campaign this month for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.